Emily Field

“A question on Cabencey in the approved schizophrenia indication, you've talked about one of the drags on sales being that, you know, clinicians aren't titrating up quickly enough to the therapeutic dose.”

“And I guess I wanted to follow up, Priya, on one of the answers you just had about, I guess, targeting that tau sweet spot, I guess, because dear nurse lowers tau indiscriminately you know with the physiological and pathological is is that what creates that sort of 50 i guess feeling on lowering tau and do you think…”

“I was just curious how you're expecting, you know, the commercial landscape in AD to have evolved by the time Zumi could be launching, given that Eggless just had the Q8-week maintenance dosing added to the label, and then how you're thinking about the potential entry of Dupixent biosimilars and how that could impact…”

“Anyway, since we started a little bit, it was just totally on me. I'm Emily Fields, covering U.S. Biopharma here at Barclays. And we are, that's how we fished Cytocadai, because I was like, we've got the whole squad.”

“I am the U.S. large-cap pharma biotech analyst here at Barclays, and we're so fortunate to have Andy Dickinson, who's the CFO of Gilead, joining us today. So thanks for coming, everybody.”